The Pharmacokinetics of Recombinant Human Erythropoietin in Balkan Endemic Nephropathy Patients
La farmacocinética de la eritropoyetina recombinante humana en pacientes con nefropatía endémica de los Balcanes
Vi¿nja Le¿aića, Nenad Petkovićb, Ivko Marićc, Branislava Miljkovićd, Katarina Vučićevićd, Sanja Simić-Ogrizovića, Vesna Pejovicc, Ljubica Djukanoviće
a University of Belgrade, Medical Faculty, Serbia, b Clinical Centre of Serbia, Department of Nephrology, Belgrade, Serbia,
b FMC Center ¿amac, BH, ¿amac, BH,
c Special Hospital for Endemic Nephropathy, Lazarevac, Serbia,
d Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia,
e Serbian Medical Society, Academy of Medical Science, Belgrade, Serbia,
Read
9846
Timeswas read the article
2923
Total PDF
6923
Total HTML
Share statistics
array:21 [ "pii" => "X201325141305291X" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2013.Apr.11800" "estado" => "S300" "fechaPublicacion" => "2013-07-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2013;33:478-85" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5329 "formatos" => array:3 [ "EPUB" => 319 "HTML" => 4271 "PDF" => 739 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699513052912" "issn" => "02116995" "doi" => "10.3265/Nefrologia.pre2013.Apr.11800" "estado" => "S300" "fechaPublicacion" => "2013-07-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2013;33:478-85" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7199 "formatos" => array:3 [ "EPUB" => 293 "HTML" => 6228 "PDF" => 678 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "La farmacocinética de la eritropoyetina recombinante humana en pacientes con nefropatía endémica de los Balcanes" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "478" "paginaFinal" => "485" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "The Pharmacokinetics of Recombinant Human Erythropoietin in Balkan Endemic Nephropathy Patients" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Vi¿nja Le¿aić, Nenad Petković, Ivko Marić, Branislava Miljković, Katarina Vučićević, Sanja Simić-Ogrizović, Vesna Pejovic, Ljubica Djukanović" "autores" => array:8 [ 0 => array:2 [ "nombre" => "Vi¿nja" "apellidos" => "Le¿aić" ] 1 => array:2 [ "nombre" => "Nenad" "apellidos" => "Petković" ] 2 => array:2 [ "nombre" => "Ivko" "apellidos" => "Marić" ] 3 => array:2 [ "nombre" => "Branislava" "apellidos" => "Miljković" ] 4 => array:2 [ "nombre" => "Katarina" "apellidos" => "Vučićević" ] 5 => array:2 [ "nombre" => "Sanja" "apellidos" => "Simić-Ogrizović" ] 6 => array:2 [ "nombre" => "Vesna" "apellidos" => "Pejovic" ] 7 => array:2 [ "nombre" => "Ljubica" "apellidos" => "Djukanović" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X201325141305291X" "doi" => "10.3265/Nefrologia.pre2013.Apr.11800" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X201325141305291X?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699513052912?idApp=UINPBA000064" "url" => "/02116995/0000003300000004/v0_201502091404/X0211699513052912/v0_201502091404/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251413052901" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2013.Feb.11872" "estado" => "S300" "fechaPublicacion" => "2013-07-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2013;33:486-94" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7080 "formatos" => array:3 [ "EPUB" => 312 "HTML" => 6046 "PDF" => 722 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Increased serum phosphate concentrations in patients with advanced chronic kidney disease treated with diuretics" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "486" "paginaFinal" => "494" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Concentraciones más elevadas de fósforo sérico en pacientes con enfermedad renal crónica avanzada tratados con diuréticos" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11872_16025_45496_en_t111872i_02_maquetacin_1.jpg" "Alto" => 1389 "Ancho" => 2173 "Tamanyo" => 810209 ] ] "descripcion" => array:1 [ "en" => "Demographic, clinical and biochemical characteristics of the total study group and the subgroups according to treatment or no treatment with diuretics" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Francisco Caravaca, Guadalupe García-Pino, Rocío Martínez-Gallardo, Flavio Ferreira-Morong, Enrique Luna, Raúl Alvarado, Enrique Ruiz-Donoso, Edgar Chavez, Edgar Chávez" "autores" => array:9 [ 0 => array:2 [ "nombre" => "Francisco" "apellidos" => "Caravaca" ] 1 => array:2 [ "nombre" => "Guadalupe" "apellidos" => "García-Pino" ] 2 => array:2 [ "nombre" => "Rocío" "apellidos" => "Martínez-Gallardo" ] 3 => array:2 [ "nombre" => "Flavio" "apellidos" => "Ferreira-Morong" ] 4 => array:2 [ "nombre" => "Enrique" "apellidos" => "Luna" ] 5 => array:2 [ "nombre" => "Raúl" "apellidos" => "Alvarado" ] 6 => array:2 [ "nombre" => "Enrique" "apellidos" => "Ruiz-Donoso" ] 7 => array:2 [ "nombre" => "Edgar" "apellidos" => "Chavez" ] 8 => array:2 [ "nombre" => "Edgar" "apellidos" => "Chávez" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699513052904" "doi" => "10.3265/Nefrologia.pre2013.Feb.11872" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699513052904?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413052901?idApp=UINPBA000064" "url" => "/20132514/0000003300000004/v0_201502091629/X2013251413052901/v0_201502091630/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X2013251413052928" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2013.Feb.11725" "estado" => "S300" "fechaPublicacion" => "2013-07-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2013;33:470-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7846 "formatos" => array:3 [ "EPUB" => 282 "HTML" => 6707 "PDF" => 857 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Costs and outcomes of endovascular treatment of thrombosed dialysis autogenous fistulae" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "470" "paginaFinal" => "477" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Costos y resultados del tratamiento endovascular de las trombosis en las fístulas autólogas para hemodiálisis" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11725_16025_41407_en_t111725_02_maquetacin_1.jpg" "Alto" => 715 "Ancho" => 2167 "Tamanyo" => 495312 ] ] "descripcion" => array:1 [ "en" => "Results of dialysis autogenous arteriovenous fistula (AVF) declotting procedures" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Luis Coentrao" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Luis" "apellidos" => "Coentrao" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699513052920" "doi" => "10.3265/Nefrologia.pre2013.Feb.11725" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699513052920?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251413052928?idApp=UINPBA000064" "url" => "/20132514/0000003300000004/v0_201502091629/X2013251413052928/v0_201502091630/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "titulo" => "The Pharmacokinetics of Recombinant Human Erythropoietin in Balkan Endemic Nephropathy Patients" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "478" "paginaFinal" => "485" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Vi¿nja Le¿aić, Nenad Petković, Ivko Marić, Branislava Miljković, Katarina Vučićević, Sanja Simić-Ogrizović, Vesna Pejovic, Ljubica Djukanović" "autores" => array:8 [ 0 => array:4 [ "nombre" => "Vi¿nja" "apellidos" => "Le¿aić" "email" => array:1 [ 0 => "visnjalezaic@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:3 [ "nombre" => "Nenad" "apellidos" => "Petković" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 2 => array:3 [ "nombre" => "Ivko" "apellidos" => "Marić" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] ] ] 3 => array:3 [ "nombre" => "Branislava" "apellidos" => "Miljković" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "affd" ] ] ] 4 => array:3 [ "nombre" => "Katarina" "apellidos" => "Vučićević" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "affd" ] ] ] 5 => array:3 [ "nombre" => "Sanja" "apellidos" => "Simić-Ogrizović" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 6 => array:3 [ "nombre" => "Vesna" "apellidos" => "Pejovic" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] ] ] 7 => array:3 [ "nombre" => "Ljubica" "apellidos" => "Djukanović" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "affe" ] ] ] ] "afiliaciones" => array:5 [ 0 => array:3 [ "entidad" => " University of Belgrade, Medical Faculty, Serbia, b Clinical Centre of Serbia, Department of Nephrology, Belgrade, Serbia, " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:3 [ "entidad" => " FMC Center ¿amac, BH, ¿amac, BH, " "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] 2 => array:3 [ "entidad" => " Special Hospital for Endemic Nephropathy, Lazarevac, Serbia, " "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] 3 => array:3 [ "entidad" => " Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia, " "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "affd" ] 4 => array:3 [ "entidad" => " Serbian Medical Society, Academy of Medical Science, Belgrade, Serbia, " "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "affe" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "La farmacocinética de la eritropoyetina recombinante humana en pacientes con nefropatía endémica de los Balcanes" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11800_16025_42020_en_t111800_03_maquetacin_1.jpg" "Alto" => 673 "Ancho" => 2181 "Tamanyo" => 274482 ] ] "descripcion" => array:1 [ "en" => "Main characteristics of the patients" ] ] ] "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara">Anemia was described as a characteristic of Balkan endemic nephropathy (BEN) in early reports on the disease,<span class="elsevierStyleSup">1,2</span> so Danilovic<span class="elsevierStyleSup">3</span> included it among the criteria for diagnosis. However, several authors reported no significant differences between anemia in BEN and other kidney diseases.<span class="elsevierStyleSup">4-6</span> Thus, although anemia in BEN patients deteriorates with progressive renal failure similarly as in patients with other kidney diseases, it was more severe in BEN patients on hemodialysis than in those with other kidney diseases.<span class="elsevierStyleSup">6,7</span> </p><p class="elsevierStylePara">We recently showed that BEN hemodialysis patients required a higher dose of recombinant human erythropoietin for maintaining the target hemoglobin level than patients with other kidney diseases.<span class="elsevierStyleSup">8</span> Several factors may contribute to the weaker hematopoietic response to erythropoietin-stimulating agents (ESA). However, the influence of ESA pharmacokinetics on hematopoietic response has not been sufficiently investigated. Pharmacokinetics studies were mostly devoted to the pharmacokinetics of diverse ESA administered by different routes,<span class="elsevierStyleSup">9-13</span> as well as to the pharmacokinetics of ESA in various groups of chronic kidney disease patients and healthy persons.<span class="elsevierStyleSup">14-16</span></p><p class="elsevierStylePara">The aim of this study was to compare the pharmacokinetics of beta-erythropoietin (beta-Epo) given subcutaneously to BEN patients and patients with other kidney diseases (non-BEN) and to evaluate the factors influencing beta-Epo kinetics.</p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">METHODS</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Study design and patients</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara">The prospective clinical study was performed according to good clinical practice and in accordance with the Declaration of Helsinki in three clinical centers. The Ethics Committee of the Clinical Center of Serbia evaluated and approved the study and the participants gave informed consent.<span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara">A total of 24 subjects was selected from the population of 256 hemodialysis patients according to the following inclusion criteria: stable individuals on regular hemodialysis, treated with beta-Epo for at least 1 year. Exclusion criteria were: treatment with ESA other than beta-Epo; anemia from causes other than chronic kidney disease - blood loss, malignancy, acute infection, hemolysis, major surgery; liver disease (twice or half normal values for transaminases); blood transfusion within one month before enrolment; severe psychiatric dysfunction or other limitations preventing the patient to give consent. Among the remaining 96 patients (40 BEN and 56 others) who met inclusion criteria, 10 with BEN and 14 with other kidney diseases were selected using <span class="elsevierStyleItalic">systematic sampling</span> i.e every 10<span class="elsevierStyleSup">th</span> patient from each group was assigned for study. The group with other kidney diseases consisted of 8 patients with glomerulonephritis, 3 with hypertensive nephropathy, 2 with reflux nephropathy and 1 with polycystic kidney disease.<span class="elsevierStyleItalic"> </span></p><p class="elsevierStylePara">All patients were treated thrice weekly for 4-5 h by<span class="elsevierStyleBold"> </span>standard bicarbonate hemodialysis using polysulphone membrane dialyzers. Data on patients’ weight, blood pressure, use of angiotensin converter enzyme inhibitors (ACEI) and angiotensin II receptor antagonists (<span class="elsevierStyleItalic">ARA II</span>), hemoglobin, rHuEpo dose and iron treatment were obtained from medical records. Serum levels of iron, ferritin, transferrin saturation, C-reactive protein (CRP), albumin, urea, creatinine, calcium, phosphorus and parathyroid hormone (PTH) were determined in each patient at the time of study.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Beta-erythropoietin administration and blood sampling</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara">All patients had been treated with beta-Epo (Epoetin-beta, Recormon<span class="elsevierStyleSup">®</span>, Roche) for more than 6 months and during the study received beta-Epo twice weekly, at the end of the first and third hemodialysis in the week. The dose of beta-Epo was adjusted to attain the hemoglobin target range defined by European best practice guidelines for the management of anemia in patients with chronic renal failure<span class="elsevierStyleSup">17</span>. In addition, iron status was assessed and supplementary iron given according to the same guidelines. </p><p class="elsevierStylePara">The last beta-Epo dose prior to pharmacokinetics blood sampling was omitted in all patients but recontinued at the first hemodialysis session after the study with the dose used before. For pharmacokinetic assessment 75U/kg of beta-Epo was administered subcutaneously at the end of the first hemodialysis in the week. Venous blood was collected into heparinized tubes before and at 2, 6, 8, 12, 24, 48, and 72 (only in five patients) h after beta-Epo administration. Blood samples were centrifuged for 10 min and plasma stored frozen until analysis. Erythropoietin (Epo) concentration was determined in all samples on the same day by chemiluminescent immunoassay for erythropoietin on an Immulite 2000 analyzer (Siemens Healthcare Diagnostics).</p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Pharmacokinetics</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara">For pharmacokinetic analysis the predose plasma level of Epo was subtracted from all postdose levels of Epo for each patient. Noncompartmental pharmacokinetic analysis using Kinetica software (Thermo Scientific, ver. 5.0) was performed in order to calculate following pharmacokinetic parameters: terminal elimination rate constant (β), half-life of elimination (t<span class="elsevierStyleInf">1/2</span>), maximum concentration (C<span class="elsevierStyleInf">max</span>), time of reaching C<span class="elsevierStyleInf">max</span> (t<span class="elsevierStyleInf">max</span>), area under the curve from time of dosing extrapolated to infinity (AUC), apparent volume of distribution (Vd/F), apparent clearance (CL/F), mean residence time (MRT).</p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Statistical analysis</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara">The results were expressed as mean values with standard deviations. The significance of differences between mean values for groups was calculated using the Mann-Whitney U test and Student’s t-test. One-way ANOVA was used to compare pharmacodynamics parameters between the groups (BEN and non-BEN). Analysis of covariance (ANCOVA) was used to adjust these differences for patient characteristics that differed between groups: age, sex, hemodialysis duration, ferritin, PTH as well as ACEI use. All analyses were performed using the SPSS (ver. 20) program.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">RESULTS</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara">The study involved 24 hemodialysis patients, 10 patients with BEN and 14 with other kidney diseases, selected from 96 patients (40 BEN and 56 others) who met the inclusion criteria<span class="elsevierStyleItalic">.</span><span class="elsevierStyleItalic"> </span>Their main characteristics are presented in Table 1. Patients with BEN were significantly older and had spent less time on hemodialysis than non-BEN patients. No between group differences were found for gender, mean weight, Kt/V and the proportion of subjects using ACEI. None of the participants used ARA II.</p><p class="elsevierStylePara">Results of laboratory analyses in the examined individuals are given in Table 2. Mean hemoglobin level for the BEN group was 112±5.5g/L and for the non-BEN group 109±4.4g/L, and mean beta-Epo doses were 87±16.5 and 66.5±28.3U/kg/week (p=.051), respectively. Iron reserves were significantly higher in the BEN than in the non-BEN group. Predialysis serum creatinine and PTH concentrations were significantly lower, and serum calcium concentration was significantly higher in the BEN than in the non-BEN group. Basal plasma Epo concentration in BEN patients ranged between 7.2 and 40.1U/L and in non-BEN patients between 6.7 and 31.2U/L, but the difference between the two groups for mean concentration was not statistically significant (20.1±10.3U/L; vs. 15.1±8.1U/L; p=.1964).</p><p class="elsevierStylePara">The individual profiles of Epo concentration after subcutaneous administration of 75U/kg of beta-Epo are presented in Figure 1 and Figure 2. After beta-Epo administration plasma Epo slowly increased and C<span class="elsevierStyleInf">max</span><span class="elsevierStyleInf"> </span>was achieved after 10.6±2.2 h in BEN patients, and after 14.6±6.16 h in non-BEN patients (p=.697). The presented profiles show greater inter-individual variability in Epo concentration but a faster decrease of Epo level during the elimination phase in non-BEN than in BEN patients.</p><p class="elsevierStylePara">The pharmacokinetic parameters of Epo are presented in Table 3. BEN patients differed markedly from non-BEN patients only in β (0.016±0.006 vs. 0.026±0.011L/h; p=.021) and t<span class="elsevierStyleInf">1/2</span> (50.24±19.12 vs. 33.79±18.91 h, p=.048). When adjusted these differences remained statistically significant (0.017±0.011 vs. 0.026±0.009; p=.038 and 57.10±24.54 vs. 33.32±9.12; p=.032 respectively). Also, the difference in other pharmacokinetic parameters presented in table 3 remained insignificant after adjustment.<span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">In the present study beta-Epo pharmacokinetics was examined in BEN and non-BEN patients. After subcutaneous administration of 75U/kg of beta-Epo, plasma Epo concentration profiles showed smaller inter-individual variability in BEN than in non-BEN patients. The value of t<span class="elsevierStyleInf">1/2</span><span class="elsevierStyleInf"> </span>was significantly greater in BEN than in non-BEN patients, but the difference in C<span class="elsevierStyleInf">max</span> and t<span class="elsevierStyleInf">max</span><span class="elsevierStyleInf"> </span>was not detected under this study design.</p><p class="elsevierStylePara">A number of pharmacokinetic studies of ESA have been published, but comparison between them is difficult due to numerous methodological differences. Recent studies were largely devoted to the pharmacokinetics of new ESAs<span class="elsevierStyleSup">10,12,14</span> and were usually carried out in healthy persons. The present study was initiated from earlier data involving 146 BEN and 94 non-BEN patients, which showed that significantly higher beta-Epo doses for reaching and maintaining target hemoglobin level were necessary in BEN than in non-BEN patients.<span class="elsevierStyleSup">8</span> In the present study the difference in the mean beta-Epo dose between the two groups examined did not reach statistical significance, probably due to the small number of patients involved. A number of factors may contribute to insufficient hematopoietic response to ESAs: iron deficiency most often caused by blood loss, secondary hyperparathyroidism, hemolysis, malignancy, malnutrition, inadequate dialysis, older age, inflammation.<span class="elsevierStyleSup">18,19</span> Most of these factors were exclusion criteria for this as well as for our previous study. In addition, none of the mentioned factors for Epo hyporesponsiveness were significantly more pronounced in BEN than in non-BEN patients, except for older age. Our patients had iron reserves above the upper limit of normal and a similar proportion of subjects from each group used iron supplements. Elevated CRP<span class="elsevierStyleSup">20,21</span> and PTH<span class="elsevierStyleSup">21</span> were found to be associated with delayed or diminished response to ESA treatment. Our groups had similar CRP levels but PTH level was significantly lower in BEN patients than in the others. ACEI and ARA II can increase the need for ESA<span class="elsevierStyleSup">18,22</span> but no significant difference was found between BEN and non-BEN patients in the relative number using ACEI (none of them used ARA II). The question arose whether the difference in beta-Epo dose could be caused by different pharmacokinetics of Epo in BEN and non-BEN patients.</p><p class="elsevierStylePara">After subcutaneous administration of beta-Epo the mean C<span class="elsevierStyleInf">max</span> of Epo in the two groups receiving the same dose did not differ significantly, but inter-individual differences in this concentration were higher in non-BEN (coefficient of variation, CV=48.4%) than in BEN patients (CV=22.4%). Similar inter-individual differences were found in time needed to reach Epo C<span class="elsevierStyleInf">max</span>. The values of C<span class="elsevierStyleInf">max</span> and t<span class="elsevierStyleInf">max</span><span class="elsevierStyleInf"> </span>are comparable to those found by other authors, taking into account the above mentioned differences in methodology.<span class="elsevierStyleSup">11,16,23,24</span> Higher inter-individual variability in non-BEN compared to BEN patients might be due to differences in group composition: the BEN group was more homogenous, consisting of patients with a single disease, while the non-BEN group included patients with diverse kidney diseases.</p><p class="elsevierStylePara">On the other hand, elimination of Epo was slower in BEN than in non-BEN patients. The value of t<span class="elsevierStyleInf">1/2</span><span class="elsevierStyleInf"> </span>obtained in non-BEN patients was comparable to that found elsewhere for hemodialysis patients<span class="elsevierStyleSup">11</span> and healthy individuals.<span class="elsevierStyleSup">25</span> This indicates that BEN patients were characterized by slower Epo elimination, and therefore with prolonged MRT as well. MRT above 60 hr had 7/10 BEN patients, but 4/14 non-BEN. Vd as primary pharmacokinetic parameter, for conventional drugs, affects the value of t<span class="elsevierStyleInf">1/2</span> in a proportional manner and not vice versa. Our results suggest that BEN patients have tendency of higher Vd values, and significantly higher t<span class="elsevierStyleInf">1/2</span> (Table 3). However, for protein and peptide drugs, dependency on active tissue uptake, binding to intra- and extravascular proteins can substantially increase the value of Vd. Therefore, not only the distribution by itself, but also the process of elimination and interaction directly with the Epo receptor on the red blood cell surface play an important role in increasing the values of Vd for Epo in comparison to its physiological distribution limited to extravascular space in the body.</p><p class="elsevierStylePara">Despite long clinical experience with ESAs, the mechanisms involved in their elimination have not been fully elucidated. It seems most likely that both native Epo and recombinant drugs are degraded following receptor-mediated uptake, mainly in the bone marrow.<span class="elsevierStyleSup">26-29</span> It might be speculated that slower elimination and greater Vd/F of Epo in BEN patients originated either from lower affinity and slower binding of Epo to its receptors or reduced internalization and/or degradation rate. In addition, recently described mechanisms independent of the Epo receptor elimination pathway,<span class="elsevierStyleSup">29</span> may also contribute to slower Epo elimination in BEN patients. </p><p class="elsevierStylePara">The main limitation of our study was the small number of patients in each group, and they were not matched in age. BEN is a slow progressive chronic kidney disease and patients who progress to end-stage renal disease usually start hemodialysis in the seventh decade of life.<span class="elsevierStyleSup">30</span> Previous studies of Epo pharmacokinetics identified age and body weight as covariates influencing absorption and elimination of Epo.<span class="elsevierStyleSup">31-33</span> In a study of beta-Epo pharmacokinetics in healthy adult males Hayashi et al.<span class="elsevierStyleSup">31</span> detected a significant negative correlation between the elimination rate constant and age and creatinine. As the main organs involved in Epo elimination are the kidneys and bone marrow and both kidney function and bone marrow cellularity decrease with age, the authors suggested that age and creatinine influence Epo elimination. Although an impact of age on Epo elimination in our patients cannot be fully excluded, neither age nor other covariates that differed between the groups was found affect Epo elimination in the ANCOVA model. On the other hand, residual renal function was maintained longer in BEN patients than in those with other kidney diseases<span class="elsevierStyleSup">34</span> and our BEN patients were shorter on hemodialysis treatment than non-BEN patients. Therefore, renal clearance of Epo could be higher in BEN than in non-BEN patients. As previous studies showed that the kidneys contribute to Epo elimination in a very minor fashion<span class="elsevierStyleSup">35</span> and residual kidney function in patients more than three years on dialysis is most often negligible, it is not expected that renal elimination of Epo could be of any influence.</p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">CONCLUSION </span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">Pharmacokinetic analysis of beta-erythropoietin found a significantly longer t<span class="elsevierStyleInf">1/2</span><span class="elsevierStyleInf"> </span>in BEN than in non-BEN patients indicating that treatment with ESA could have different effects in different diseases. These findings need to be confirmed in a well-controlled study with a larger sample size in order to establish population pharmacokinetics of beta-Epo in BEN patients, to evaluate the effects of physiopathological factors on the disposition kinetics of beta-Epo and to find potential predictive factors for dosage individualization.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Acknowledgments</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara">This work was conducted as a part of projects No 175089 and 175023 funded by the Ministry of Science, Education and Technological Development, Belgrade, Republic of Serbia.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflicts of interest</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">The authors declare that they have no conflicts of interest related to the contents of this article.</p><p class="elsevierStylePara"><a href="grande/11800_16025_42020_en_t111800_03_maquetacin_1.jpg" class="elsevierStyleCrossRefs"><img src="11800_16025_42020_en_t111800_03_maquetacin_1.jpg" alt="Main characteristics of the patients"></img></a></p><p class="elsevierStylePara">Table 1. Main characteristics of the patients</p><p class="elsevierStylePara"><a href="grande/11800_16025_42021_en_t211800_03_maquetacin_1.jpg" class="elsevierStyleCrossRefs"><img src="11800_16025_42021_en_t211800_03_maquetacin_1.jpg" alt="Results of laboratory analyses in examined patients"></img></a></p><p class="elsevierStylePara">Table 2. Results of laboratory analyses in examined patients</p><p class="elsevierStylePara"><a href="grande/11800_16025_42022_en_t311800_03_maquetacin_1.jpg" class="elsevierStyleCrossRefs"><img src="11800_16025_42022_en_t311800_03_maquetacin_1.jpg" alt="Individual and mean (± SD) values of pharmacokinetic parameters of rHuEpo after subcutaneous administration of 75 U/kg to examined patients"></img></a></p><p class="elsevierStylePara">Table 3. Individual and mean (± SD) values of pharmacokinetic parameters of rHuEpo after subcutaneous administration of 75 U/kg to examined patients</p><p class="elsevierStylePara"><a href="grande/11800_16025_42023_en_f111800_03_maquetacin_1.jpg" class="elsevierStyleCrossRefs"><img src="11800_16025_42023_en_f111800_03_maquetacin_1.jpg" alt="Plasma erythropoietin concentration profiles in BEN patients after subcutaneous administration of 75 U/kg of beta-erythropoietin"></img></a></p><p class="elsevierStylePara">Figure 1. Plasma erythropoietin concentration profiles in BEN patients after subcutaneous administration of 75 U/kg of beta-erythropoietin</p><p class="elsevierStylePara"><a href="grande/11800_16025_42024_en_f211800_03_maquetacin_1.jpg" class="elsevierStyleCrossRefs"><img src="11800_16025_42024_en_f211800_03_maquetacin_1.jpg" alt="Plasma erythropoietin concentration profiles in non-BEN patients after subcutaneous administration of 75U/kg of beta-erythropoietin"></img></a></p><p class="elsevierStylePara">Figure 2. Plasma erythropoietin concentration profiles in non-BEN patients after subcutaneous administration of 75U/kg of beta-erythropoietin</p>" "pdfFichero" => "P1-E557-S4299-A11800-EN.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:3 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440127" "palabras" => array:1 [ 0 => "Farmacocinética" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440129" "palabras" => array:1 [ 0 => "Eritropoyetina recombinante humana" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec440131" "palabras" => array:1 [ 0 => "Nefropatía endémica de los Balcanes" ] ] ] "en" => array:3 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440128" "palabras" => array:1 [ 0 => "Pharmacokinetics" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440130" "palabras" => array:1 [ 0 => "Human recombinant erythropoietin" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec440132" "palabras" => array:1 [ 0 => "Balkan endemic nephropathy" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Antecedentes:</span> Los pacientes con nefropatía endémica de los Balcanes (NEB) en hemodiálisis necesitan una dosis más elevada de eritropoyetina recombinante humana que los pacientes con otras enfermedades renales para poder mantener el nivel de hemoglobina deseado. <span class="elsevierStyleBold">Objetivos:</span><span class="elsevierStyleBold"> </span>Comparar la farmacocinética de la eritropoyetina beta administrada subcutáneamente a pacientes en hemodiálisis con NEB u otras enfermedades renales.<span class="elsevierStyleBold"> </span><span class="elsevierStyleBold">Métodos:</span> A 10 pacientes hemodializados con NEB y 14 pacientes hemodializados con otras enfermedades renales se les administró subcutáneamente eritropoyetina (EPO) recombinante humana (75 U/kg). El nivel de EPO en plasma previo a la dosis se sustrajo de todos los niveles que se obtuvieron tras administrarla. Los parámetros farmacocinéticos relevantes se calcularon tras el análisis farmacocinético no compartimental con ayuda de la aplicación Kinetica (Thermo Scientific, versión 5.0).<span class="elsevierStyleBold"> </span><span class="elsevierStyleBold">Resultados:</span> Aunque la concentración basal de EPO en el plasma era similar en pacientes con NEB (20,1 ± 10,3 U/l) y en pacientes con otras enfermedades renales (15,1 ± 8,1 U/l; p = 0,1964), se apreciaron diferencias significativas entre los grupos con respecto a la constante de eliminación (0,016 ± 0,006 vs. 0,026 ± 0,011 h<span class="elsevierStyleSup">-1</span>; p = 0,020) y a la semivida de eliminación (50,24 ± 19,12 vs. 33,79 ± 18,91 h, p = 0,048). Estas diferencias resultaron igualmente significativas tras ajustar los valores en función de las características de los pacientes (edad, sexo, duración de la hemodiálisis, ferritina, hormona paratiroidea y uso de inhibidores de la enzima de conversión de la angiotensina). No obstante, no se observaron diferencias significativas entre los grupos en los siguientes parámetros ni antes ni después de efectuar los ajustes pertinentes: concentración máxima de EPO, tiempo en alcanzar la concentración máxima de EPO, área bajo la curva extrapolada al infinito a partir de la administración de la dosis, aclaramiento y tiempo medio de permanencia de la EPO.<span class="elsevierStyleBold"> </span><span class="elsevierStyleBold">Conclusión:</span> El análisis farmacocinético de la eritropoyetina beta reveló que la semivida de eliminación era significativamente más larga en los pacientes con NEB, hallazgo que debe ser confirmado en un estudio bien controlado con una muestra más grande.</p>" ] "en" => array:1 [ "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Background:</span> Balkan endemic nephropathy (BEN) hemodialysis patients require a higher dose of recombinant human erythropoietin for maintaining target hemoglobin level than patients with other kidney diseases. <span class="elsevierStyleBold">Objectives: </span>Comparison of the pharmacokinetics of beta-erythropoietin given subcutaneously to hemodialysis patients with BEN or other kidney diseases (non-BEN).<span class="elsevierStyleBold"> Methods:</span> Recombinant human erythropoietin (75U/kg) was administered subcutaneously to 10 BEN and 14 non-BEN hemodialysis patients. The predose plasma level of erythropoietin (Epo) was subtracted from all postdose levels. The relevant pharmacokinetic parameters were calculated after noncompartmental pharmacokinetic analysis using Kinetica software (Thermo Scientific, ver.5.0).<span class="elsevierStyleBold"> Results:</span> Although basal plasma Epo concentration was similar in BEN (20.1±10.3U/L) and non-BEN (15.1±8.1U/L; p=.1964) patients, there were significant differences between the groups for elimination rate constant (0.016±0.006 vs 0.026±0.011 hr<span class="elsevierStyleSup">-1</span>; p=.020) and elimination half-life (50.24±19.12 vs 33.79±18.91 hr, p=.048). These differences remained significant after adjustment for patient characteristics (age, sex, hemodialysis duration, ferritin, PTH and ACEI use). No significant differences between groups were found in maximal Epo concentration, time to maximum Epo concentration, area under the curve from time of dosing extrapolated to infinity, clearance, mean residence time of Epo between groups both before and after adjustment.<span class="elsevierStyleBold"> Conclusion:</span> Pharmacokinetic analysis of beta-erythropoietin detected a significantly longer elimination half-life in BEN than in non BEN patients. This finding needs to be confirmed in a well-controlled study with a larger sample size.</p>" ] ] "multimedia" => array:5 [ 0 => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11800_16025_42020_en_t111800_03_maquetacin_1.jpg" "Alto" => 673 "Ancho" => 2181 "Tamanyo" => 274482 ] ] "descripcion" => array:1 [ "en" => "Main characteristics of the patients" ] ] 1 => array:8 [ "identificador" => "fig2" "etiqueta" => "Tab. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11800_16025_42021_en_t211800_03_maquetacin_1.jpg" "Alto" => 747 "Ancho" => 2170 "Tamanyo" => 356396 ] ] "descripcion" => array:1 [ "en" => "Results of laboratory analyses in examined patients" ] ] 2 => array:8 [ "identificador" => "fig3" "etiqueta" => "Tab. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11800_16025_42022_en_t311800_03_maquetacin_1.jpg" "Alto" => 2033 "Ancho" => 2180 "Tamanyo" => 993709 ] ] "descripcion" => array:1 [ "en" => "Individual and mean (± SD) values of pharmacokinetic parameters of rHuEpo after subcutaneous administration of 75 U/kg to examined patients" ] ] 3 => array:8 [ "identificador" => "fig4" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11800_16025_42023_en_f111800_03_maquetacin_1.jpg" "Alto" => 796 "Ancho" => 1016 "Tamanyo" => 101243 ] ] "descripcion" => array:1 [ "en" => "Plasma erythropoietin concentration profiles in BEN patients after subcutaneous administration of 75 U/kg of beta-erythropoietin" ] ] 4 => array:8 [ "identificador" => "fig5" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11800_16025_42024_en_f211800_03_maquetacin_1.jpg" "Alto" => 808 "Ancho" => 1016 "Tamanyo" => 109463 ] ] "descripcion" => array:1 [ "en" => "Plasma erythropoietin concentration profiles in non-BEN patients after subcutaneous administration of 75U/kg of beta-erythropoietin" ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003300000004/v0_201502091629/X201325141305291X/v0_201502091630/en/main.assets" "Apartado" => array:4 [ "identificador" => "35446" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Special Originals" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003300000004/v0_201502091629/X201325141305291X/v0_201502091630/en/P1-E557-S4299-A11800-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X201325141305291X?idApp=UINPBA000064" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 6 | 7 | 13 |
| 2024 October | 46 | 53 | 99 |
| 2024 September | 55 | 31 | 86 |
| 2024 August | 71 | 67 | 138 |
| 2024 July | 61 | 39 | 100 |
| 2024 June | 70 | 47 | 117 |
| 2024 May | 73 | 35 | 108 |
| 2024 April | 42 | 44 | 86 |
| 2024 March | 53 | 23 | 76 |
| 2024 February | 50 | 37 | 87 |
| 2024 January | 25 | 36 | 61 |
| 2023 December | 32 | 28 | 60 |
| 2023 November | 48 | 31 | 79 |
| 2023 October | 41 | 38 | 79 |
| 2023 September | 43 | 34 | 77 |
| 2023 August | 40 | 27 | 67 |
| 2023 July | 86 | 39 | 125 |
| 2023 June | 49 | 33 | 82 |
| 2023 May | 56 | 35 | 91 |
| 2023 April | 39 | 20 | 59 |
| 2023 March | 40 | 17 | 57 |
| 2023 February | 40 | 20 | 60 |
| 2023 January | 43 | 25 | 68 |
| 2022 December | 100 | 29 | 129 |
| 2022 November | 57 | 32 | 89 |
| 2022 October | 76 | 44 | 120 |
| 2022 September | 39 | 40 | 79 |
| 2022 August | 35 | 44 | 79 |
| 2022 July | 44 | 46 | 90 |
| 2022 June | 30 | 31 | 61 |
| 2022 May | 38 | 44 | 82 |
| 2022 April | 34 | 54 | 88 |
| 2022 March | 38 | 59 | 97 |
| 2022 February | 42 | 51 | 93 |
| 2022 January | 44 | 44 | 88 |
| 2021 December | 42 | 58 | 100 |
| 2021 November | 45 | 42 | 87 |
| 2021 October | 30 | 47 | 77 |
| 2021 September | 38 | 43 | 81 |
| 2021 August | 50 | 44 | 94 |
| 2021 July | 39 | 42 | 81 |
| 2021 June | 36 | 26 | 62 |
| 2021 May | 46 | 51 | 97 |
| 2021 April | 91 | 86 | 177 |
| 2021 March | 74 | 79 | 153 |
| 2021 February | 31 | 71 | 102 |
| 2021 January | 26 | 37 | 63 |
| 2020 December | 44 | 29 | 73 |
| 2020 November | 43 | 37 | 80 |
| 2020 October | 39 | 20 | 59 |
| 2020 September | 31 | 21 | 52 |
| 2020 August | 44 | 18 | 62 |
| 2020 July | 32 | 19 | 51 |
| 2020 June | 37 | 36 | 73 |
| 2020 May | 51 | 31 | 82 |
| 2020 April | 38 | 25 | 63 |
| 2020 March | 33 | 23 | 56 |
| 2020 February | 42 | 29 | 71 |
| 2020 January | 74 | 37 | 111 |
| 2019 December | 76 | 45 | 121 |
| 2019 November | 86 | 39 | 125 |
| 2019 October | 75 | 20 | 95 |
| 2019 September | 96 | 22 | 118 |
| 2019 August | 50 | 11 | 61 |
| 2019 July | 66 | 30 | 96 |
| 2019 June | 45 | 17 | 62 |
| 2019 May | 47 | 19 | 66 |
| 2019 April | 82 | 55 | 137 |
| 2019 March | 59 | 27 | 86 |
| 2019 February | 32 | 21 | 53 |
| 2019 January | 44 | 22 | 66 |
| 2018 December | 87 | 31 | 118 |
| 2018 November | 105 | 10 | 115 |
| 2018 October | 147 | 19 | 166 |
| 2018 September | 76 | 13 | 89 |
| 2018 August | 73 | 12 | 85 |
| 2018 July | 51 | 13 | 64 |
| 2018 June | 55 | 14 | 69 |
| 2018 May | 54 | 12 | 66 |
| 2018 April | 72 | 10 | 82 |
| 2018 March | 57 | 7 | 64 |
| 2018 February | 49 | 10 | 59 |
| 2018 January | 48 | 4 | 52 |
| 2017 December | 47 | 9 | 56 |
| 2017 November | 47 | 11 | 58 |
| 2017 October | 39 | 9 | 48 |
| 2017 September | 47 | 17 | 64 |
| 2017 August | 37 | 9 | 46 |
| 2017 July | 47 | 16 | 63 |
| 2017 June | 39 | 28 | 67 |
| 2017 May | 39 | 15 | 54 |
| 2017 April | 42 | 14 | 56 |
| 2017 March | 21 | 9 | 30 |
| 2017 February | 54 | 15 | 69 |
| 2017 January | 26 | 14 | 40 |
| 2016 December | 47 | 7 | 54 |
| 2016 November | 58 | 9 | 67 |
| 2016 October | 118 | 10 | 128 |
| 2016 September | 182 | 1 | 183 |
| 2016 August | 184 | 5 | 189 |
| 2016 July | 213 | 7 | 220 |
| 2016 June | 137 | 0 | 137 |
| 2016 May | 112 | 0 | 112 |
| 2016 April | 97 | 0 | 97 |
| 2016 March | 71 | 0 | 71 |
| 2016 February | 90 | 0 | 90 |
| 2016 January | 97 | 0 | 97 |
| 2015 December | 96 | 0 | 96 |
| 2015 November | 90 | 0 | 90 |
| 2015 October | 81 | 0 | 81 |
| 2015 September | 84 | 0 | 84 |
| 2015 August | 88 | 0 | 88 |
| 2015 July | 77 | 0 | 77 |
| 2015 June | 55 | 0 | 55 |
| 2015 May | 75 | 0 | 75 |
| 2015 April | 12 | 0 | 12 |
Show all
